Effect of acute magnesium administration on the frequency of ventricular arrhythmia in patients with heart failure

Carla A. Sueta, Susan W. Clarke, Stephanie H. Dunlap, Lynda Jensen, Mary Beth Blauwet, Gary Koch, J. Herbert Patterson, Kirkwood F. Adams

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: There is a high incidence of ventricular arrhythmia and sudden death in patients with heart failure. Unfortunately, currently available antiarrhythmic agents have only limited efficacy and may result in proarrhythmia and hemodynamic deterioration in these patients. Methods and Results: We studied the acute effect of intravenous magnesium chloride on the frequency and severity of ventricular arrhythmia in 30 patients with symptomatic heart failure using a double-blind, placebo-controlled crossover design. The left ventricular ejection fraction was 23.0±8.0% (mean±SD). No patient had a history of symptomatic ventricular arrhythmia or was receiving antiarrhythmic agents, calcium channel antagonists, or β-blockers. Patients were randomized to receive placebo (5% dextrose [D5W] in water alone) or magnesium chloride in D5W given as a bolus of 0.3 mEq/kg over 10 minutes followed by a maintenance infusion of 0.08 mEq/kg per hour for 24 hours. The magnesium concentrations 30 minutes and 24 hours after the bolus were 3.6±0.1 and 4.2±0.1 mg/dL, respectively. There was no significant change in serum potassium concentration during magnesium administration. Blinded analysis revealed that administration of intravenous magnesium chloride, compared with placebo, significantly decreased total ventricular ectopy per hour (mean±SEM, 70±26 versus 149±64, P<.001), couplets per day (23±11 versus 94±59, P=.007), and episodes of ventricular tachycardia per day (0.8±0.2 versus 2.6±1.0, P = .051). Conclusions: Intravenous magnesium chloride administration reduces the frequency of ventricular arrhythmia in patients with symptomatic heart failure.

Original languageEnglish (US)
Pages (from-to)660-666
Number of pages7
JournalCirculation
Volume89
Issue number2
DOIs
StatePublished - Feb 1994

Fingerprint

Magnesium
Cardiac Arrhythmias
Magnesium Chloride
Heart Failure
Placebos
Calcium Channel Blockers
Ventricular Tachycardia
Sudden Death
Intravenous Administration
Stroke Volume
Cross-Over Studies
Potassium
Hemodynamics
Maintenance
Glucose
Water
Incidence
Serum

Keywords

  • arrhythmia
  • heart failure
  • magnesium

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Effect of acute magnesium administration on the frequency of ventricular arrhythmia in patients with heart failure. / Sueta, Carla A.; Clarke, Susan W.; Dunlap, Stephanie H.; Jensen, Lynda; Blauwet, Mary Beth; Koch, Gary; Patterson, J. Herbert; Adams, Kirkwood F.

In: Circulation, Vol. 89, No. 2, 02.1994, p. 660-666.

Research output: Contribution to journalArticle

Sueta, CA, Clarke, SW, Dunlap, SH, Jensen, L, Blauwet, MB, Koch, G, Patterson, JH & Adams, KF 1994, 'Effect of acute magnesium administration on the frequency of ventricular arrhythmia in patients with heart failure', Circulation, vol. 89, no. 2, pp. 660-666. https://doi.org/10.1161/01.CIR.89.2.660
Sueta, Carla A. ; Clarke, Susan W. ; Dunlap, Stephanie H. ; Jensen, Lynda ; Blauwet, Mary Beth ; Koch, Gary ; Patterson, J. Herbert ; Adams, Kirkwood F. / Effect of acute magnesium administration on the frequency of ventricular arrhythmia in patients with heart failure. In: Circulation. 1994 ; Vol. 89, No. 2. pp. 660-666.
@article{0855fde57c2d49f79094046be18e1e54,
title = "Effect of acute magnesium administration on the frequency of ventricular arrhythmia in patients with heart failure",
abstract = "Background: There is a high incidence of ventricular arrhythmia and sudden death in patients with heart failure. Unfortunately, currently available antiarrhythmic agents have only limited efficacy and may result in proarrhythmia and hemodynamic deterioration in these patients. Methods and Results: We studied the acute effect of intravenous magnesium chloride on the frequency and severity of ventricular arrhythmia in 30 patients with symptomatic heart failure using a double-blind, placebo-controlled crossover design. The left ventricular ejection fraction was 23.0±8.0{\%} (mean±SD). No patient had a history of symptomatic ventricular arrhythmia or was receiving antiarrhythmic agents, calcium channel antagonists, or β-blockers. Patients were randomized to receive placebo (5{\%} dextrose [D5W] in water alone) or magnesium chloride in D5W given as a bolus of 0.3 mEq/kg over 10 minutes followed by a maintenance infusion of 0.08 mEq/kg per hour for 24 hours. The magnesium concentrations 30 minutes and 24 hours after the bolus were 3.6±0.1 and 4.2±0.1 mg/dL, respectively. There was no significant change in serum potassium concentration during magnesium administration. Blinded analysis revealed that administration of intravenous magnesium chloride, compared with placebo, significantly decreased total ventricular ectopy per hour (mean±SEM, 70±26 versus 149±64, P<.001), couplets per day (23±11 versus 94±59, P=.007), and episodes of ventricular tachycardia per day (0.8±0.2 versus 2.6±1.0, P = .051). Conclusions: Intravenous magnesium chloride administration reduces the frequency of ventricular arrhythmia in patients with symptomatic heart failure.",
keywords = "arrhythmia, heart failure, magnesium",
author = "Sueta, {Carla A.} and Clarke, {Susan W.} and Dunlap, {Stephanie H.} and Lynda Jensen and Blauwet, {Mary Beth} and Gary Koch and Patterson, {J. Herbert} and Adams, {Kirkwood F.}",
year = "1994",
month = "2",
doi = "10.1161/01.CIR.89.2.660",
language = "English (US)",
volume = "89",
pages = "660--666",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Effect of acute magnesium administration on the frequency of ventricular arrhythmia in patients with heart failure

AU - Sueta, Carla A.

AU - Clarke, Susan W.

AU - Dunlap, Stephanie H.

AU - Jensen, Lynda

AU - Blauwet, Mary Beth

AU - Koch, Gary

AU - Patterson, J. Herbert

AU - Adams, Kirkwood F.

PY - 1994/2

Y1 - 1994/2

N2 - Background: There is a high incidence of ventricular arrhythmia and sudden death in patients with heart failure. Unfortunately, currently available antiarrhythmic agents have only limited efficacy and may result in proarrhythmia and hemodynamic deterioration in these patients. Methods and Results: We studied the acute effect of intravenous magnesium chloride on the frequency and severity of ventricular arrhythmia in 30 patients with symptomatic heart failure using a double-blind, placebo-controlled crossover design. The left ventricular ejection fraction was 23.0±8.0% (mean±SD). No patient had a history of symptomatic ventricular arrhythmia or was receiving antiarrhythmic agents, calcium channel antagonists, or β-blockers. Patients were randomized to receive placebo (5% dextrose [D5W] in water alone) or magnesium chloride in D5W given as a bolus of 0.3 mEq/kg over 10 minutes followed by a maintenance infusion of 0.08 mEq/kg per hour for 24 hours. The magnesium concentrations 30 minutes and 24 hours after the bolus were 3.6±0.1 and 4.2±0.1 mg/dL, respectively. There was no significant change in serum potassium concentration during magnesium administration. Blinded analysis revealed that administration of intravenous magnesium chloride, compared with placebo, significantly decreased total ventricular ectopy per hour (mean±SEM, 70±26 versus 149±64, P<.001), couplets per day (23±11 versus 94±59, P=.007), and episodes of ventricular tachycardia per day (0.8±0.2 versus 2.6±1.0, P = .051). Conclusions: Intravenous magnesium chloride administration reduces the frequency of ventricular arrhythmia in patients with symptomatic heart failure.

AB - Background: There is a high incidence of ventricular arrhythmia and sudden death in patients with heart failure. Unfortunately, currently available antiarrhythmic agents have only limited efficacy and may result in proarrhythmia and hemodynamic deterioration in these patients. Methods and Results: We studied the acute effect of intravenous magnesium chloride on the frequency and severity of ventricular arrhythmia in 30 patients with symptomatic heart failure using a double-blind, placebo-controlled crossover design. The left ventricular ejection fraction was 23.0±8.0% (mean±SD). No patient had a history of symptomatic ventricular arrhythmia or was receiving antiarrhythmic agents, calcium channel antagonists, or β-blockers. Patients were randomized to receive placebo (5% dextrose [D5W] in water alone) or magnesium chloride in D5W given as a bolus of 0.3 mEq/kg over 10 minutes followed by a maintenance infusion of 0.08 mEq/kg per hour for 24 hours. The magnesium concentrations 30 minutes and 24 hours after the bolus were 3.6±0.1 and 4.2±0.1 mg/dL, respectively. There was no significant change in serum potassium concentration during magnesium administration. Blinded analysis revealed that administration of intravenous magnesium chloride, compared with placebo, significantly decreased total ventricular ectopy per hour (mean±SEM, 70±26 versus 149±64, P<.001), couplets per day (23±11 versus 94±59, P=.007), and episodes of ventricular tachycardia per day (0.8±0.2 versus 2.6±1.0, P = .051). Conclusions: Intravenous magnesium chloride administration reduces the frequency of ventricular arrhythmia in patients with symptomatic heart failure.

KW - arrhythmia

KW - heart failure

KW - magnesium

UR - http://www.scopus.com/inward/record.url?scp=0028032003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028032003&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.89.2.660

DO - 10.1161/01.CIR.89.2.660

M3 - Article

C2 - 7508827

AN - SCOPUS:0028032003

VL - 89

SP - 660

EP - 666

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 2

ER -